Related Experiment Video

Updated: May 29, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Species D adenoviruses as oncolytics against B-cell cancers

Christopher Y Chen1, Julien S Senac, Eric A Weaver

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55902, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 6, 2011
PubMed
Abstract

Insights

Species D adenoviruses show unique potential for killing B-cell cancers, unlike other types. These oncolytic viruses could be a new treatment for B-cell malignancies like lymphoma and myeloma.

Area of Science:

  • Virology
  • Oncology
  • Immunology

Background:

  • Oncolytic viruses are anticancer agents that use viral replication to kill cancer cells.
  • Adenovirus serotype 5 (Ad5) is effective against solid tumors but not B-cell cancers due to low coxsackie and adenoviral receptor (CAR) expression.
  • Investigating alternative adenoviruses is crucial for expanding oncolytic virotherapy to B-cell malignancies.

Purpose of the Study:

  • To identify adenoviruses with enhanced potency against B-cell cancers.
  • To explore the adenovirus virome for novel oncolytic agents targeting B-cell malignancies.

Main Methods:

  • In vitro testing of 15 adenoviruses from species B, C, D, E, and F against B-cell cancer cell lines and primary patient cells.
  • In vivo studies using B-cell cancer xenografts in immunodeficient mice to evaluate viral efficacy.
  • Assessment of viral infection, replication, and cell killing capabilities.

Main Results:

  • Species D adenoviruses demonstrated the most effective killing of various B-cell cancer cell lines in vitro.
  • Significant activity was observed against primary marginal zone lymphoma and CD138+ myeloma cells.
  • In vivo, Ad26 and Ad45 (species D) treatments delayed lymphoma xenograft growth.

Conclusions:

  • Species D adenoviruses exhibit unique infectivity and replication in B-cell cancers compared to other adenovirus species.
  • These findings highlight distinct viral biology in B cells, supporting species D adenoviruses as promising oncolytics.
  • Further development of novel species D adenoviruses is warranted for B-cell cancer therapy.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...